Targets › AGT
3 programs from 2 companies in 3 trials: 1 Phase 2, 1 Phase 1, 1 Phase 3; Cardiovascular; next expected readout Apr 2028.
Essential component of the renin-angiotensin system (RAS), a potent regulator of blood pressure, body fluid and electrolyte homeostasis..; FUNCTION: [Angiotensin-2]: Acts directly on vascular smooth muscle as a potent vasoconstrictor, affects cardiac contractility and heart rate through its action on the sympathetic nervous system, and alters renal sodium and water absorption through its ability to stimulate the…. (UniProt, P01019)
Open in Phaseline: the race on AGT, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Alnylam Pharmaceuticals | Zilebesiran Small interfering RNA (siRNA) targeting angiotensinogen (AGT) mRNA | AGT | Phase 3 | High Risk Cardiovascular Disease | Sep 2030 |
| Alnylam Pharmaceuticals | ALN-AGT01 RVR RNA interference therapeutic targeting AGT; reduces angiotensinogen production | AGT | Phase 2 | Hypertension | Apr 2028 |
| CRISPR Therapeutics | CTX340 CRISPR-Cas9 therapy targeting angiotensinogen (AGT) gene disruption in liver | AGT | Phase 1 | Hypertension | Jul 2028 |
Hypertension (2) High Risk Cardiovascular Disease (1)
mixed (1), small molecule (1), other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.